Related Experiment Videos
International dosage differences in fluoxetine clinical trials
Scott Patten1, Andrea Cipriani, Paolo Brambilla
1Department of Community Health Sciences, University of Calgary, Alberta.
Summary
Antidepressant dosages in clinical trials differed significantly by region. Trials in the US used higher fluoxetine dosages compared to Europe, highlighting international variations in treatment practices.
Area of Science:
- Pharmacology
- Clinical Trials
- Psychiatry
Background:
- International variations in mood disorder treatment are suspected.
- Antidepressant prescribing patterns may differ globally.
- Clinical trial methodologies can reflect regional practices.
Purpose of the Study:
- To investigate international differences in antidepressant dosages within clinical trials.
- To analyze dosage variations for fluoxetine and comparator drugs across countries.
- To utilize data from a Cochrane review on fluoxetine trials.
Main Methods:
- Systematic review of 132 comparative clinical trials.
- Data abstraction of methodological features and results into an electronic database.
- Comparison of mean and maximum fluoxetine dosages between the US and Europe.
- Calculation of defined daily dosage (DDD) ratios for comparator medications.
Main Results:
- Higher mean and maximum fluoxetine dosages were observed in US trials (mean 49.18 mg) versus European trials (mean 29.98 mg).
- Similar trends of higher dosages were found for comparison antidepressants in US trials.
- Data limitations prevented analysis of dosage practices in regions outside the US and Europe.
Conclusions:
- International differences in clinical trial conduct may reflect or influence prescriber behavior.
- Observed dosage variations pose challenges to evidence-based medicine principles.
- Further research is needed to understand global antidepressant prescribing patterns.